bioLytical® Laboratories Inc. based in Richmond, BC, Canada is a privately-owned Canadian Company federally incorporated in 2002.
Today, the company sells and markets its INSTI® rapid diagnostic test product line, including its unique HIV test supported by worldwide regulatory approvals in the US, Canada, European Union and other countries that accept the CE certification. Our product line provides a highly accurate test results in as little as 60 seconds which translates into a compelling value proposition for patients, healthcare professionals, payers and public health organizations. We have an active R&D program and our pipeline includes INSTI® tests for diseases such as Hepatitis C and Ebola. The company also provides contract services to adapt the INSTI® platform to meet custom functional and technical diagnostic testing requirements.
bioLytical’s mission is to improve the quality of people’s lives by providing innovative solutions for infectious disease diagnosis, the first step in the linkage of patients to appropriate care and treatment.
bioLytical’s vision is to be a global leader in the research, development and commercialization of rapid, point-of-care in vitro medical diagnostic devices.
We pursue novel ways of engaging with diverse healthcare systems to maximize access to our innovative technology platform and products.
We strive to do the right thing and behave responsibly towards all stakeholders including regulators, customers and colleagues
We strive to deliver a great customer experience for those who buy and use our products.
We collaborate as individuals and as teams with stakeholders seeking to advance the diagnosis and treatment of infectious diseases.
We are persistent and determined to overcome hurdles and solve problems that prevent the diagnosis and treatment of infectious diseases.